Physician profile
Robert G Stenberg
NPI 1164453841
$4,159.46
in general payments reported to CMS, 2019-2025
25 companies · $759 in 2025
The $759 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $120 · 2021: $390 · 2022: $1,154 · 2023: $881 · 2024: $492 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,131.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $452.13 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $399.86 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $361.16 | 2019-2024 | Lifevest |
| Boston Scientific Corporation | $330.82 | 2019-2022 | |
| Abbott Laboratories | $292.79 | 2022-2024 | Jot Dx, Mitraclip |
| Novo Nordisk INC | $249.66 | 2022-2024 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $246.14 | 2023-2024 | Camzyos |
| Scpharmaceuticals INC. | $243.85 | 2024-2025 | |
| Edwards Lifesciences Corporation | $169.54 | 2022 | |
| Bridgebio Pharma, INC. | $144.43 | 2025 | Attruby |
| Cvrx, INC. | $141.86 | 2025 | Barostim Neo System |
| Zoll Respicardia, INC. | $136.38 | 2021 | |
| Atricure, INC. | $134.46 | 2022 | |
| Lilly USA, LLC | $124.51 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $120.30 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $115.60 | 2021 | |
| Angiodynamics, INC. | $102.51 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.21 | 2022 | |
| Pfizer INC. | $81.20 | 2022 | |
| Penumbra, INC. | $77.60 | 2025 | Penumbra System, Indigo System |
| Samsung Hme America, INC. | $50.00 | 2022 | |
| Recor Medical INC | $28.00 | 2025 | Paradise Ultrasound Renal Denervation System |
| Kestra Medical Technology Services, INC. | $28.00 | 2023 | Assure Wcd |
| Medtronic, INC. | $14.72 | 2023 | Micra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.